# US 2024/0417370 A1 · Lipids for use in lipid nanoparticle formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0417370 A1
- Document ID: US20240417370A1
- Status: Published application
- Kind: A1
- Application number: 18/655,061
- Filed: 2024-05-03
- Published: 2024-12-19
- Earliest claimed: 2023-05-05
- Applicants: Acuitas Therapeutics, Inc.
- Inventors: Jason Samuel Tan; Stephen Paul Arns; Julia Gatenyo
- Web page: https://patentgrep.com/patent/US20240417370A1

## CPC

- C07C 237/06: having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 48/0025: {wherein the non-active part clearly interacts with the delivered nucleic acid}
- A61K 48/0033: {the non-active part being non-polymeric}
- A61K 48/0091: {Purification or manufacturing processes for gene therapy compositions}
- C07D 305/06: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
- C07D 305/08: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
- C07D 307/22: Nitrogen atoms not forming part of a nitro radical
- C07D 309/14: Nitrogen atoms not forming part of a nitro radical
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- A61K 48/0041: {the non-active part being polymeric}
- C07C 2601/02: with a three-membered ring
- C07C 2601/04: with a four-membered ring
- C07C 2601/08: the ring being saturated
- C07C 2601/14: The ring being saturated
- C07C 2601/18: with a ring being at least seven-membered
- C07C 2602/18: the ring system containing six carbon atoms
- C07C 2602/40: the bicyclo ring system containing six carbon atoms
- C07C 2602/50: Spiro compounds
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Compounds are provided having the following Structure (I): or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein R1, R1, L1, L2, L2a, L2b, and A are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

## Claims

### Claim 1

A compound having the following structure (I):
or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:
A is a 3-10 membered carbocyclic or oxygen-containing heterocyclic ring optionally substituted with one or more fluoro, hydroxyl, C1-C6 alkyl, or C1-C6 alkylhydroxyl substituents;
R1 is —NRaC(═O)R3 or —C(═O)NRbRc;
R2 is —NRdC(═O)R4 or —C(═O)NReRf;
R3 and R4 are each independently C6-C24 alkyl or C6-C24 alkenyl;
Ra, Rb, Rd and Re are each independently H, C1-C20 alkyl or C2-C20 alkenyl;
Re and Rf are each independently C1-C20 alkyl or C2-C20 alkenyl;
L1 and L2 are each independently a direct bond or C1-C6 alkylene; and
L2a and L2b are each independently C4-C12 alkylene;
wherein each alkyl, alkylene, and alkenyl is optionally substituted with one or more fluoro.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R1 is —C(═O)NRbRc and R2 is —C(═O)NReRf.

### Claim 3 (depends on 1)

The compound of claim 1, wherein R1 is —NRaC(═O)R3 and R2 is —NRdC(═O)R4.

### Claim 4 (depends on 1)

The compound of claim 1, wherein R1 is —NRaC(═O)R3 and R2 is —C(═O)NReRf.

### Claim at position 5

5-6. (canceled)

### Claim 7 (depends on 1)

The compound of claim 1, wherein Ra, Rb, Rc, Rd, Re and Rf are each independently C8, C9, C10, or C19 alkyl.

### Claim at position 7

8-9. (canceled)

### Claim 10 (depends on 1)

The compound of claim 1, wherein R3 and R4 are each independently C8, C9 or C10 alkyl.

### Claim at position 9

11-12. (canceled)

### Claim 13 (depends on 1)

The compound of claim 1, wherein L1 is a direct bond, C1 alkylene, or C2 alkylene.

### Claim at position 11

14-15. (canceled)

### Claim 16 (depends on 1)

The compound of claim 1, wherein L2 is a direct bond, C1 alkylene, or C2 alkylene.

### Claim 17

(canceled)

### Claim 18 (depends on 1)

The compound of claim 1, wherein L2a and L2b are each independently C6, C7, C8, C9, or C10 alkylene.

### Claim 19 (depends on 1)

The compound of claim 1, wherein A is a C3-C10 carbocyclic ring optionally substituted with one or more hydroxyl or C1-C6 alkylhydroxyl substituents.

### Claim 20 (depends on 19)

The compound of claim 19, wherein A is monocyclic, bicyclic or spirocyclic.

### Claim at position 17

21-22. (canceled)

### Claim 23 (depends on 19)

The compound of claim 19, wherein A is a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, oxiraneyl, oxetaneyl, tetrahydrofuranyl, or tetrahydropyranyl, each optionally substituted with one or more hydroxyl, or C1-C6 alkylhydroxyl substituents.

### Claim at position 19

24-29. (canceled)

### Claim 30 (depends on 1)

The compound of claim 1, wherein
has one of the following structures:
or a stereoisomer thereof.

### Claim 31

(canceled)

### Claim 32 (depends on 1)

The compound of claim 1, wherein one or more of Ra, Rb, Rc, Rd, Re, Rf, L1, L2, L2a and L2b are substituted with one or more fluorine atoms.

### Claim 33 (depends on 1)

The compound of claim 1, wherein the compound is a racemic mixture of one of the following enantiomeric pairs or combinations of Structure (I):

### Claim 34 (depends on 1)

The compound of claim 1, having one of the following structures:

### Claim 35 (depends on 1)

A lipid nanoparticle comprising the compound of claim 1 and a therapeutic agent.

### Claim 36

(canceled)

### Claim 37 (depends on 35)

The lipid nanoparticle of claim 35, further comprising one or more excipient selected from neutral lipids, steroids and polymer conjugated lipids.

### Claim 38 (depends on 37)

The lipid nanoparticle of claim 37, comprising one or more neutral lipids selected from DSPC, DPPC, DMPC, DOPC, POPC, DOPE and SM.

### Claim at position 29

39-40. (canceled)

### Claim 41 (depends on 37)

The lipid nanoparticle of claim 37, wherein the steroid is cholesterol.

### Claim at position 31

42-45. (canceled)

### Claim 46 (depends on 37)

The lipid nanoparticle of claim 37, wherein the polymer conjugated lipid is a pegylated lipid has the following Structure (II):
or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein:
R10 and R11 are each independently a straight or branched, alkyl, alkenyl or alkynyl from 10 to 30 carbon atoms, wherein the alkyl, alkenyl or alkynyl is optionally interrupted by one or more ester bonds; and
w has a value ranging from 30 to 60.

### Claim at position 33

47-49. (canceled)

### Claim 50 (depends on 35)

The lipid nanoparticle of claim 35, wherein the therapeutic agent comprises a nucleic acid selected from antisense and messenger RNA.

### Claim 51 (depends on 35)

A method for administering a therapeutic agent to a patient in need thereof, the method comprising preparing or providing the lipid nanoparticle of claim 35 and administering the composition to the patient.

### Claim 52 (depends on 35)

A pharmaceutical composition comprising the lipid nanoparticle of claim 35 and a pharmaceutically acceptable diluent or excipient.

### Claim 53 (depends on 52)

A method for inducing expression of a protein in a patient in need thereof, comprising administering the pharmaceutical composition of claim 52 to the patient, wherein the lipid nanoparticle comprises an mRNA encoding the protein.

### Claim at position 38

54-56. (canceled)
